
Enanta Pharmaceuticals (ENTA) Stock
Clinical stage company developing antiviral therapies through partnerships. Here's the price, business snapshot, and what's worth knowing about Enanta Pharmaceuticals in November 2026.
Enanta Pharmaceuticals (ENTA) is a clinical-stage biotechnology company focused on designing and developing small-molecule antiviral therapies. Investors should know the company operates through a pipeline of preclinical and clinical candidates aimed at treating viral illnesses; revenues may be limited while programmes advance. Enanta often seeks partnerships or licensing deals with larger pharmaceutical companies to share development costs and commercialise products. The stock’s market capitalisation is around $306.94M, reflecting investor expectations about future pipeline milestones and licensing potential. Drug development is inherently high-risk and binary — clinical setbacks or regulatory delays can materially affect value, while successful trials or deals can be catalysts. This summary is educational, not personalised investment advice; investors should consider company filings, clinical data, financial position, and their own risk tolerance before acting.
Enanta Pharmaceuticals (ENTA) Stock Forecast
Analyst price target, next 12 months
$19.27
+79.4% vs today's $10.74
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Enanta Pharmaceuticals have a consensus 12-month target of $19.27, above the current price of $10.74.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 26 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Six-Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Enanta Pharmaceuticals' stock, expecting it to rise to $19.27.
Financial Health
Enanta Pharmaceuticals has moderate revenue and cash flow, but its book value per share is low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Catalysts
Clinical readouts and licensing deals can move the share price significantly, though outcomes are uncertain and timelines can be long.
Scientific Focus
Specialises in small-molecule antivirals, which can offer targeted, oral treatment options — but technical and regulatory hurdles remain.
Partnership Potential
Strategic collaborations with larger pharma can fund development and accelerate market access, though terms and timing vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.